Ion Exchange Q1 FY27: Profit Plummets Despite Revenue Surge

Ion Exchange (India) Limited navigated a mixed financial landscape in the first quarter of fiscal year 2027. Despite a notable 20% year-over-year increase in consolidated operating income, reaching INR 701 crores, the company faced a significant contraction in profitability.

EBITDA experienced a sharp 49% decline to INR 32 crores, while net profit plummeted to just INR 3 crores. This downturn reflects challenges stemming from legacy projects and operational costs.

Q1 FY27 Key Financials

• Operating income: INR 701 crores (up 20% YoY)
• EBITDA: INR 32 crores (down 49% YoY)
• EBITDA margin: 4.54% (down from 8.95% in Q1 FY26)
• Net profit: INR 3 crores
• PAT margin: 0.44%

The company attributed the significant drop in profit to delays in legacy projects, stabilization costs incurred at its Roha plant, and persistent higher input costs. This confluence of factors led to an initial 10.72% dip in the company’s stock on the earnings report day, although it later recovered some ground.

Strategic Reclassification for Clarity

In response to these challenges and to enhance transparency for investors, Ion Exchange has strategically reclassified its reporting segments. The previous three segments are now expanded to five distinct categories, aiming to provide a clearer view of its diverse business mix.

Management emphasized a strategic pivot towards products, chemicals, and services, intending to reduce the company’s reliance on large, often complex, project execution. This move signals a shift in operational focus for the coming periods.

Segmental Performance Breakdown

• Treatment Solutions: Revenue of INR 210 crores (up 14% YoY), but an EBIT loss of INR 17 crores due to legacy projects.
• Industrial Products: Revenue of INR 105 crores (up 14% YoY), with EBIT increasing 145% to INR 13 crores.
• Lifecycle Services: Revenue of INR 72 crores (up 28% YoY), and EBIT of INR 7 crores (up 22% YoY).
• Specialty Chemicals: Revenue of INR 230 crores (up 21% YoY), yet EBIT declined 52% to INR 22 crores, impacted by geopolitical factors and Goa facility costs.
• Consumer Products: Revenue of INR 112 crores (up 33% YoY), reporting a loss of INR 34 lakhs, indicating a modest improvement.

Investments & Future-Ready Solutions

Ion Exchange is actively investing in several growth initiatives to bolster its market position and product portfolio. These include significant capacity expansions at key facilities across India.

• Five-fold capacity expansion for ion exchange resins at the Roha plant.
• Six-fold expansion for pharma resins at the Ankleshwar facility.
• Establishment of a second membrane plant in Goa to produce a comprehensive range of membranes.

These investments are integral to a broader strategy focused on enhancing market share and transitioning into higher-margin product lines, including non-solvent resin manufacturing and advanced membrane technologies. The company is also targeting emerging water treatment solutions.

• Seawater desalination
• Treatment for ‘forever chemicals’ (PFAS)
• Semiconductor water systems
• Green hydrogen applications

Management remains confident in its ability to achieve double-digit profitability over time, driven by an improved business mix and these strategic investments.